Global competition for early coronavirus vaccine doses is already fierce, months ahead of any approvals, as wealthy countries move to secure supplies.
The U.S. government has pledged over $3 billion to secure hundreds of millions of doses of vaccines under development by Britain's AstraZeneca Plc and by U.S. drug giant Pfizer Inc
and Germany's BioNTech SE <22UAy.F>.
Malpass said the World Bank plan aimed to put poor and middle-income countries, where the virus is spreading most rapidly, on the same footing as richer countries by ensuring they have financing to secure supplies and a system for distribution, which will encourage drugmakers to meet their demand.
Without early doses that can bring outbreaks under control, many of these countries risk economic collapse that will push hundreds of millions of people back into poverty.
"Our goal is to alter the course of the pandemic for the low- and middle-income developing countries," Malpass said. "This is a market signal to the manufacturers that there will be financing available for the developing countries and there will be demand. We will begin asking the manufacturers to begin creating allocations for these countries."Malpass said the World Bank also was asking wealthy countries that have "over-reserved" more doses than they will ultimately need to release those doses to poorer countries.
He added that he is working to persuade countries that equitable distribution of vaccines "is important to the world and will give a better outcome for the world."
Separately, Brent McIntosh, U.S. Treasury undersecretary for international affairs, told a Foreign Policy magazine forum on Tuesday that wealthy countries were working on broad vaccine availability.
"There have been intense conversations among various developed countries on ensuring that there are vaccines available in the developing world and those conversations are ongoing at the highest levels," said McIntosh, who oversees U.S. involvement in the World Bank and the International Monetary Fund.
The World Bank program will disburse grant or loan funding to countries, and will be able to select any vaccine that meets safety criteria, including approval from multiple "highly respected, stringent regulatory agencies," such as those in the United States, Canada, Japan and several European countries, Malpass said.
The World Bank's private-sector arm, the International Financing Corp, in July launched a $4 billion financing platform to boost investment in developing country production of vaccines and other critical health products.
(Reporting by David Lawder; Editing by Lisa Shumaker, David Gregorio and Jonathan Oatis)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.